Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Annovis Bio (NYSE: ANVS) has announced plans for an underwritten public offering of common stock and warrants. ThinkEquity will serve as the sole book-running manager, with a 45-day option to purchase up to an additional 15% of shares and/or warrants to cover over-allotments.
The company intends to use the proceeds primarily for working capital and general corporate purposes, including the continued clinical development of their lead compound, Buntanetap. The offering will be made through a shelf registration statement on Form S-3 filed with the SEC.
Annovis Bio is a late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s disease. The completion and terms of the offering are subject to market conditions.
Annovis Bio (NYSE: ANVS) ha annunciato piani per un’offerta pubblica di azioni ordinarie e warrant sotto un contratto di garanzia. ThinkEquity fungerà da unico gestore principale del libro, con un’opzione di 45 giorni per acquistare fino al 15% aggiuntivo di azioni e/o warrant per coprire sovravvendite.
La società intende utilizzare i proventi principalmente per il capitale circolante e scopi aziendali generali, inclusa la prosecuzione dello sviluppo clinico del loro composto principale, Buntanetap. L’offerta sarà effettuata attraverso una dichiarazione di registrazione a scaffale sul modulo S-3 depositata presso la SEC.
Annovis Bio è una società clinica a fase avanzata che si concentra su terapie transformative per le malattie neurodegenerative, in particolare su Alzheimer e Parkinson. Il completamento e i termini dell’offerta sono soggetti alle condizioni di mercato.
Annovis Bio (NYSE: ANVS) ha anunciado planes para una oferta pública subyacente de acciones ordinarias y garantías. ThinkEquity será el único gerente de libro de órdenes, con una opción de 45 días para comprar hasta un 15% adicional de acciones y/o garantías para cubrir sobreasignaciones.
La compañía tiene la intención de utilizar los ingresos principalmente para capital de trabajo y propósitos corporativos generales, incluida la continuación del desarrollo clínico de su compuesto principal, Buntanetap. La oferta se realizará a través de una declaración de registro en estante en el Formulario S-3 presentado ante la SEC.
Annovis Bio es una compañía de plataforma de medicamentos clínicos en etapa tardía que se centra en terapias transformadoras para enfermedades neurodegenerativas, particularmente Alzheimer y Parkinson. La finalización y los términos de la oferta están sujetos a las condiciones del mercado.
Annovis Bio (NYSE: ANVS)는 보통주 및 워런트에 대한 공모 계획을 발표했습니다. ThinkEquity는 단독 책 관리자로 선정되었으며, 45일 이내에 추가 주식 및/또는 워런트를 최대 15%까지 구매할 수 있는 옵션이 제공됩니다.
회사는 수익금을 주로 운영 자본 및 일반 회사 목적에 사용하고자 하며, 이에는 주요 화합물인 Buntanetap의 지속적인 임상 개발이 포함됩니다. 공모는 SEC에 제출된 S-3 양식의 등록 선언을 통해 이루어질 것입니다.
Annovis Bio는 신경퇴행성 질환, 특히 알츠하이머 및 파킨슨병에 대한 변혁적 치료법에 중점을 둔 후기 단계의 임상 약물 플랫폼 회사입니다. 공모의 완료 및 조건은 시장 상황에 따라 달라질 수 있습니다.
Annovis Bio (NYSE: ANVS) a annoncé des projets d’offre publique souscrite d’actions ordinaires et de bons de souscription. ThinkEquity agira en tant que seul gestionnaire du livre, avec une option de 45 jours pour acquérir jusqu’à 15 % d’actions et/ou de bons supplémentaires pour couvrir les surallocations.
La société prévoit d’utiliser les produits principalement pour son fonds de roulement et à des fins générales d’entreprise, y compris le développement clinique continu de son composé principal, Buntanetap. L’offre sera réalisée par le biais d’une déclaration d’enregistrement sur étagère sous le formulaire S-3 déposé auprès de la SEC.
Annovis Bio est une entreprise de plateforme de médicaments cliniques en phase avancée, axée sur des thérapies transformatrices pour les maladies neurodégénératives, en particulier la maladie d’Alzheimer et la maladie de Parkinson. La réalisation et les modalités de l’offre sont soumises aux conditions du marché.
Annovis Bio (NYSE: ANVS) hat Pläne für ein öffentliches Angebot von Stammaktien und Warrants bekannt gegeben. ThinkEquity wird als alleiniger Buchführungsmanager fungieren, mit einer 45-tägigen Option, bis zu 15% zusätzliche Aktien und/oder Warrants zu erwerben, um Überplatzierungen abzudecken.
Das Unternehmen beabsichtigt, die Erlöse hauptsächlich für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden, einschließlich der fortgesetzten klinischen Entwicklung ihres Hauptverbindung, Buntanetap. Die Emission erfolgt über einen registrierten Shelf-Registrierungsantrag auf Formular S-3, der bei der SEC eingereicht wurde.
Annovis Bio ist ein Unternehmen mit einer klinischen Plattform in der späten Phase, das sich auf transformative Therapien für neurodegenerative Erkrankungen konzentriert, insbesondere auf Alzheimer und Parkinson-Krankheit. Der Abschluss und die Bedingungen des Angebots unterliegen den Marktbedingungen.
Positive
- Potential capital raise to fund clinical development of Buntanetap
- Shelf registration statement already effective with SEC
Negative
- Potential dilution for existing shareholders through new stock issuance
- Uncertain offering terms and completion timeline
- Additional warrant offering may create further dilution
Insights
This proposed public offering represents a critical financing event for Annovis Bio that warrants careful investor attention. The offering structure, combining common stock and warrants, typically indicates a need for substantial capital while providing sweeteners (warrants) to attract investors in the current challenging biotech funding environment.
Several key aspects deserve scrutiny: First, the timing suggests urgency in raising capital, as biotech companies typically aim to secure funding from a position of strength rather than necessity. The inclusion of warrants, while potentially attractive to new investors, signals increased future dilution potential beyond the initial offering.
The use of proceeds for working capital and Buntanetap’s clinical development is crucial, as the company focuses on both Alzheimer’s and Parkinson’s disease programs. However, without specified offering size or pricing, investors should monitor the final terms closely, as these will indicate market reception and the extent of dilution.
The shelf registration’s recent effectiveness (February 12, 2024) suggests this offering was planned, though market conditions may have accelerated the timeline. The 45-day over-allotment option could provide additional capital if market reception is positive, but also represents potential additional dilution of up to 15% above the base offering.
For current shareholders, this offering presents a double-edged sword: while it provides necessary capital for advancing clinical programs, it comes at the cost of ownership dilution. The warrant component could create additional pressure on the stock price as these instruments approach their exercise dates.
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it intends to offer to sell common stock and warrants in an underwritten public offering. All of the common stock and warrants are to be sold by the Company.
ThinkEquity is acting as sole book-running manager for the offering.
The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants sold in this offering to cover over-allotments, if any.
The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes, including the continued clinical development of the Company’s lead compound, Buntanetap.
The securities in the offering described above will be offered and sold pursuant to a shelf registration statement on Form S-3, as amended (File No. 333-276814), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 1, 2024 and declared effective on February 12, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying base prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying base prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying base prospectus, which provide more information about the Company and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Annovis Bio, Inc.:
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Forward-Looking Statements:
This press release contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company’s plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company’s clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company’s periodic filings with the SEC, including those listed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
FAQ
What is the purpose of Annovis Bio’s (ANVS) proposed public offering?
The offering aims to raise funds for working capital and general corporate purposes, specifically to support the continued clinical development of Buntanetap, their lead compound for neurodegenerative diseases.
How many additional shares can ThinkEquity purchase in ANVS’s offering?
ThinkEquity has a 45-day option to purchase up to an additional 15% of the shares and/or warrants to cover over-allotments.
When was ANVS’s shelf registration statement declared effective?
The shelf registration statement on Form S-3 was declared effective by the SEC on February 12, 2024.
What therapeutic areas does Annovis Bio (ANVS) focus on?
Annovis Bio focuses on developing transformative therapies for neurodegenerative diseases, specifically Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Who is the book-running manager for ANVS’s public offering?
ThinkEquity is acting as the sole book-running manager for the offering.
